Celcuity VIKTORIA-1 Subgroup Shows Longer PFS Than Alpelisib
In PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer without liver metastases, median PFS was 21.5 months with the triplet regimen and 11.5 months with the doublet, versus 9.1 months with alpelisib plus fulvestrant. TEAE discontinuations were 5% and 4%, respectively, versus 19% with alpelisib.
Celcuity reported VIKTORIA-1 subgroup results: in PIK3CA MT HR+/HER2- ABC without liver mets, median PFS was 21.5 months (triplet) and 11.5 months (doublet) vs 9.1 months with alpelisib+fulvestrant; TEAE discontinuations were 5%/4% vs 19% for alpelisib.Material DetailsContext by AI AnalystThis is a…